

HEALTHCARE & LIFE SCIENCES

Industry Update | March 2021



Healthcare & Life Sciences Industry Overview

OUTSOURCED MEDICAL DEVICE SERVICES: MARKET UPDATE

From imaging equipment to examination tables, every piece of equipment used in a healthcare setting requires rigorous maintenance to perform its intended function safely and effectively. That critical job falls to a large and highly fragmented universe of outsourced medical device services companies.

In this Q&A, we explore the key opportunities and trends in this important sector and identify which types of providers show the most growth potential going forward.

[Read the article.](#)

M & A ENVIRONMENT ⁽¹⁾

There have been roughly 330 M&A transactions in the healthcare and life sciences (HCLS) industry since the beginning of 2021, worth roughly \$56 billion, compared with approximately \$222 billion for all of 2020.

Notable recent transactions include the acquisition of Pandion Therapeutics, Inc. (NasdaqGS: PAND) by Merck Sharp & Dohme Corp.; PRA Health Sciences, Inc. (NasdaqGS: PRAH) by ICON Public Limited Company (NasdaqGS: ICLR); and Cognate BioServices, Inc. by Charles River Laboratories International, Inc. (NYSE: CRL)

PUBLIC COMPANY PERFORMANCE ⁽¹⁾

Stock prices increased for many healthcare and life sciences companies during the past three months. In fact, the Harris Williams HCLS Composite Index increased 10.7%, while the S&P increased 4.7%. Notable sector increases include assisted living (increased 77.0%), disease management (increased 34.2%), and retail pharmacy (increased 22.9%).

Industry-wide stock prices have experienced increases as a whole; the HCLS Composite Index showed an increase over the past 12 months of 28.3%. At the category level, products and devices grew by 31.6% on average over the past 12 months, followed by provider-based services increasing 31.6%, and payor, provider, and pharmacy support stock prices increasing 28.3%. Specific stock price growth leaders over the past year include disease management (87.8%), acute care hospitals (73.6%), and life sciences tools (54.8%).

INDUSTRY NEWS

If you haven't paid attention to the financial health of large insurers during the pandemic, it's never been better. Unfortunately, the same cannot be said of hospitals and patients. Both are struggling to hurdle escalating barriers to scheduled care due to prior authorization requirements. While prior authorizations are intended to reduce "unnecessary" procedures, they result in multiple burdens on providers and patients. No-auth denials are the first financial impact, and these can be as high as 10% of a provider's net revenue. To offset these losses providers must often bill unsuspecting patients who are not prepared for the surprise bill for a covered procedure.^(A)


Home-based care companies, including Amazon Care and two health systems, are lobbying Congress to make permanent changes to home healthcare reimbursement policies. Intermountain Healthcare and Ascension are two of the founding members of the Moving Health Home coalition, which aims to change the way policymakers think about the home as a site of clinical service. The COVID-19 pandemic exposed the untapped potential of home-based clinical care and the opportunity for a more robust set of services ranging from primary care to hospital-level treatment, the coalition said in a press release. "The advent of telehealth, remote monitoring, digital therapeutics, provider home visiting, medical records sharing, and other technology has shown that care in the home can be at least equivalent to, if not better than, care offered in facilities," the organizations said.^(B)

It's hard to overstate the lasting downstream impact of COVID-19 on substance use disorder (SUD). Already deemed a public health crisis in 2016 by then-Surgeon General Vivek Murthy, the affect stemming from months of social isolation, fear and economic despair is on track to be devastating without a dramatic shift in treatment and payment models. To date, discussions about how to "fix" this crisis and repair the addiction treatment landscape centered around crucial pieces to the puzzle, namely increased access via telemedicine and removing the "X waiver," a widely condemned federal regulation that requires providers to obtain this waiver in order to prescribe buprenorphine to patients who suffer from opioid use disorder.^(C)

M&A Overview⁽¹⁾


Announced Healthcare & Life Sciences M&A

QUARTERLY M&A ACTIVITY



Healthcare & Life Sciences M&A Trends

ANNOUNCED HEALTHCARE & LIFE SCIENCES TRANSACTIONS



Announced Private Equity M&A Activity

PEG INVESTMENTS BY SEGMENT (LAST 3 YEARS)

HC&LS Industry Segment	Number of Companies
Health Care Facilities	135
Health Care Services	131
Health Care Equipment	37
Pharmaceuticals	25
Health Care Technology	47
Life Sciences Tools and Services	24
Health Care Supplies	13
Health Care Distributors	8
Biotechnology	18
Managed Health Care	7

Note: Transactions based on publicly available information


HEALTHCARE TRANSACTION HIGHLIGHTS

Announced	Target	Buyer
2/25/2021	Pandion Therapeutics, Inc. (NasdaqGS:PAND)	Merck Sharp & Dohme Corp.
2/24/2021	PRA Health Sciences, Inc. (NasdaqGS:PRAH)	ICON Public Limited Company (NasdaqGS:ICLR)
2/17/2021	Cognate BioServices, Inc.	Charles River Laboratories International, Inc. (NYSE:CRL)
2/1/2021	Viel Bio, Inc. (NasdaqGS:VIE)	Horizon Therapeutics USA, Inc.
1/21/2021	Preventice Solutions, Inc.	Boston Scientific Corporation (NYSE:BSX)
1/20/2021	Cardiva Medical, Inc.	Haemonetics Corporation (NYSE:HAE)
1/19/2021	Capsule Technologies, Inc.	Koninklijke Philips N.V. (ENXTAM:PHIA)
1/19/2021	Mesa Biotech, Inc.	Thermo Fisher Scientific Inc. (NYSE:TMO)


LTM DEAL STATISTIC⁽¹⁾

Aggregate Value (\$bn)	Number of Deals	Median Transaction Multiples	
		TEV/Rev	TEV/EBITDA
\$268.1	1,569	3.6x	13.2x

MEDIAN HEALTHCARE & LIFE SCIENCES TRANSACTION MULTIPLES




PEG INVESTMENTS




Debt Markets Overview

Key Credit Statistics⁽²⁾


QUARTERLY HEALTHCARE LOAN VOLUME




AVERAGE SPREAD ON HEALTHCARE LOANS



CREDIT METRICS



AVERAGE SECONDARY SPREAD



SELECT HEALTHCARE & LIFE SCIENCES DEBT OFFERINGS⁽³⁾

(by deal amount)

Date Effective	Borrower Name	Description	Amount (\$ mm)	Tranche	Rating	Spread
02/23/21	BrightSpring Health Services	General Purpose	\$550	Term Loan B	NR / NR	L+ 375
02/23/21	Schumacher Group	General Purpose	\$530	Term Loan B	NR / NR	L+ 475
02/25/21	NextPharma GmbH	Acquisition	\$290	Term Loan B	NR / NR	L+ 375
02/01/21	Australian Clinical Labs Pty Ltd	Dividend Recapitalization	\$200	Revolver/Term Loan	NR / NR	N/A
02/04/21	3400 Cannon Place LLC	Real estate loan	\$67	Term Loan	NR / NR	L+ 300

Public Markets Overview⁽¹⁾


KEY TRADING STATISTICS

(Details begin on page 10)

Sector	Number of Companies	Aggregate Enterprise Value (\$ mm)	Change in Stock Price		Median TEV / LTM Multiples		Median TEV / Forward Multiples		
			3 mos.	12 mos.	Revenue	EBITDA	Revenue	EBITDA	
Payor, Provider, & Pharmacy Support Services	Clinical Laboratories	2	\$48,290	6.3%	22.8%	2.1x	7.1x	2.0x	8.4x
	Contract Pharma Manufacturing	2	\$21,270	0.5%	43.2%	9.8x	0.0x	8.3x	0.0x
	Contract Research Organizations	6	\$118,382	16.4%	47.3%	3.9x	21.6x	3.4x	17.7x
	Disease Management	1	\$1,589	34.2%	87.8%	3.6x	11.0x	3.3x	10.4x
	Healthcare Staffing	3	\$10,535	15.6%	17.2%	1.4x	13.0x	1.3x	11.5x
	HMO - Medical	7	\$641,919	(2.4%)	25.5%	1.0x	11.6x	1.0x	11.7x
	Information Services	9	\$34,743	(2.7%)	16.7%	4.2x	18.0x	3.7x	12.2x
	Retail Pharmacy	3	\$254,131	22.9%	15.1%	0.6x	7.7x	0.6x	11.9x
	Specialty Managed Care	3	\$16,719	10.9%	16.0%	3.3x	19.4x	5.5x	32.4x
	Products & Devices	Dental Products	2	\$129,515	0.8%	12.5%	3.7x	15.6x	3.4x
Durable Medical Equipment		4	\$40,721	2.4%	20.7%	2.7x	15.1x	2.7x	13.1x
Life Sciences Tools		3	\$314,471	5.3%	54.8%	5.9x	18.2x	5.4x	16.8x
Medical Devices and Products		11	\$1,272,029	7.3%	27.3%	6.4x	26.1x	5.4x	18.5x
Medical / Surgical / Dental Supplies & Distribution		6	\$91,045	(2.4%)	20.6%	0.3x	8.3x	0.3x	7.7x
Spec Pharma and Generics		12	\$83,146	15.4%	41.0%	2.5x	9.2x	2.4x	8.7x
Acute-Care Hospitals		3	\$127,599	12.4%	73.6%	1.3x	8.4x	1.2x	7.8x
Assisted Living		2	\$6,937	77.0%	(15.0%)	2.2x	10.5x	1.9x	21.8x
Diagnostic Imaging		2	\$17,891	(1.5%)	16.4%	3.5x	18.1x	3.1x	16.5x
Dialysis Services		3	\$59,058	(7.1%)	(17.3%)	2.1x	7.8x	1.8x	8.8x
Provider-Based Services	Home Care, Hospice, and Home Infusion	5	\$23,310	(1.1%)	34.2%	3.5x	23.5x	3.2x	21.6x
	Long-Term Care	2	\$6,465	11.0%	39.0%	1.6x	10.3x	2.1x	16.8x
	Physician Practice Management	1	\$2,646	21.5%	42.9%	1.5x	11.4x	1.5x	11.4x
	Behavioral Health / Management	5	\$24,570	0.0%	2.3%	1.2x	12.0x	2.3x	8.7x
	Surgicenters / Rehabilitation	4	\$28,822	15.1%	33.6%	2.6x	12.2x	2.4x	14.7x
	Payor, Provider, & Pharmacy Support Services	36	\$1,147,579	2.1%	28.3%	1.8x	12.7x	1.6x	12.6x
	Products & Devices	38	\$1,930,926	6.2%	31.6%	5.7x	19.8x	5.0x	16.3x
	Provider-Based Services	27	\$297,297	5.9%	31.6%	2.4x	12.7x	2.2x	12.4x
	HW HCLS Composite Index	101	\$3,375,803	10.7%	28.3%	4.3x	17.1x	3.8x	14.9x
	S&P 500			4.7%	29.0%				


PUBLIC COMPANY SECTOR PERFORMANCE

(12-month % change in stock price)



Equity Markets Overview

Healthcare & Life Sciences Industry Stock Performance⁽¹⁾



TOP EQUITY OFFERINGS⁽⁴⁾

(by proceeds)

Closing Date	Issuer	Ticker	Transaction Type	Gross Proceeds (\$ mm)
02/26/21	Arya Sciences Acquisition Corp IV	NASDAQ:ARYA	IPOs	\$130
02/26/21	Ibere Pharmaceuticals	NYSE:IBERU	IPOs	\$120
02/12/21	Decibel Therapeutics	NASDAQ:DBTX	IPOs	\$127
02/12/21	Talis Biomedical Corporation	NASDAQ:TLIS	IPOs	\$254
02/12/21	NexImmune	NASDAQ:NEXI	IPOs	\$126
02/11/21	Apria, Inc.	NASDAQ:APR	IPOs	\$150
02/11/21	Bioventus Inc.	NASDAQ:BVS	IPOs	\$125
02/11/21	Signify Health, Inc.	NASDAQ:SGFY	IPOs	\$564

(A): Comprised of public company comparables listed on pages 10-16

M&A Transactions

Announced U.S. Healthcare & Life Sciences M&A⁽¹⁾

Announced	Target	Seller	Buyer	Enterprise Value (\$mm)	Enterprise Value / LTM			Private Equity Involvement
					Sales	EBITDA	EBIT	
2/26/2021	The Herbal Care Center, Inc.	-	Verano Holdings Corp. (CNSX:VRNO)	\$38.1	-	-	-	No
2/26/2021	MDLIVE, Inc.	-	Evernorth	-	-	-	-	No
2/26/2021	Silicon Therapeutics LLC	-	Roivant Sciences, Inc.	\$450.0	-	-	-	No
2/26/2021	Motif BioSciences, Inc.	Motif Bio plc (AIM:MTFB)	Orange Avenue Technologies, LLC	-	-	-	-	No
2/25/2021	Pandion Therapeutics, Inc. (NasdaqGS:PAND)	-	Merck Sharp & Dohme Corp.	\$1,580.8	209.2x	-	-	No
2/25/2021	Acreage Florida, Inc.	Acreage Holdings, Inc. (CNSX:ACRG.A.U)	Red White & Bloom Brands Inc. (CNSX:RWB)	\$60.0	-	-	-	No
2/25/2021	Sentry Neuromonitoring, LLC	-	Assure Holdings Corp. (TSXV:IOM)	\$3.8	-	-	-	No
2/25/2021	Onegevity Health, LLC	-	Thorne HealthTech	-	-	-	-	No
2/25/2021	Substantially All of the Assets of the Lowell Herb	Lowell Herb Co.	Lowell Farms Inc. (CNSX:LOWL)	\$38.7	-	-	-	No
2/25/2021	Little Creek Recovery	-	-	-	-	-	-	No
2/25/2021	Gilbert Hospital LLC	-	Nutex Health, Inc.	\$10.5	-	-	-	No
2/24/2021	TheraPearl and Biofreeze of Performance Health, LLC	Performance Health, LLC	Reckitt Benckiser Group plc (LSE:RB)	-	-	-	-	No
2/24/2021	PRA Health Sciences, Inc. (NasdaqGS:PRAH)	-	ICON Public Limited Company (NasdaqGS:ICLR)	\$12,235.6	3.8x	26.1x	43.1x	No
2/24/2021	Arsenal Oils & Extracts, LLC	-	CannAmerica Brands Corp. (CNSX:CANA)	\$2.0	-	-	-	No
2/24/2021	Quality Division of Quantros, Inc.	Quantros, Inc.	CareOperative, LLC	-	-	-	-	No
2/24/2021	Magnetic Resonance Innovations, Inc.	-	SpinTech, Inc.	-	-	-	-	No
2/24/2021	Three Active Dispensaries and One Cultivation and Production Facility in Arizona	-	Verano Holdings Corp. (CNSX:VRNO)	-	-	-	-	No
2/24/2021	Simplify Medical, Inc.	Life Sciences Partners BV; M.H. Carnegie & Co.	NuVasive, Inc. (NasdaqGS:NUVA)	\$195.9	-	-	-	Yes
2/24/2021	U.S. Nursing Corporation/Fastaff Travel Nursing, LLC	Thomas H. Lee Partners, L.P.	Trilantic Capital Management L.P.; Cornell Capital LLC	-	-	-	-	Yes
2/24/2021	Nurse On Call/Arc Richmond Place/ARC Therapy Services	American Retirement Corporation; Brookdale Senior Living Inc. (NYSE:BKD)	H3OT Corp., LLC	\$500.0	-	-	-	No
2/24/2021	KA Medical, LLC	-	Merit Medical Systems, Inc. (NasdaqGS:MMSI)	\$14.4	-	-	-	No
2/24/2021	HGE Health Care Solutions, LLC	Ben Franklin Technology Partners of Southeastern Pennsylvania, Investment Arm	Vapotherm, Inc. (NYSE:VAPO)	\$24.5	-	-	-	Yes
2/23/2021	Evo National, Inc.	-	The IMA Group	-	-	-	-	No
2/23/2021	Guide Therapeutics, LLC	Greatpoint Investment Management, LLC; GV; Biomatics Capital Partners	Beam Therapeutics Inc. (NasdaqGS:BEAM)	\$440.0	-	-	-	Yes
2/23/2021	Cardiolink Corporation	-	CB Scientific, Inc. (OTCPK:CBSC)	-	-	-	-	No
2/23/2021	Six Practices in Florida	-	Northwestern Management Services LLC	-	-	-	-	No
2/23/2021	All Assets of Health Outcomes Sciences, Inc.	Health Outcomes Sciences, Inc	Terumo Corporation (TSE:4543)	-	-	-	-	No
2/23/2021	PBHS, Inc.	-	Revenue Well Systems, LLC	-	-	-	-	No
2/23/2021	Scrubbs Healthcare/Zactly Healthcare Solutions	-	Gale Healthcare Solutions, LLC	-	-	-	-	No
2/23/2021	GenetiRate LLC	-	IMV Technologies SA	-	-	-	-	No
2/23/2021	HealthEx Courier, LLC	-	Associated Couriers, Inc.	-	-	-	-	No

M&A Transactions

Announced U.S. Healthcare & Life Sciences M&A⁽¹⁾

Announced	Target	Seller	Buyer	Enterprise Value (\$mm)	Enterprise Value / LTM			Private Equity Involvement
					Sales	EBITDA	EBIT	
2/22/2021	D&S Residential Services, LP	Comvest Partners	National Mentor Holdings, Inc.	-	-	-	-	Yes
2/22/2021	Cobra Investments Management Inc.	-	PMC Group, Inc.	-	-	-	-	No
2/22/2021	MedRisk, Inc.	The Carlyle Group Inc. (NasdaqGS:CG)	CVC Capital Partners Limited	-	-	-	-	Yes
2/19/2021	WCCT Global, LLC	Medivate Partners LLC	Altasciences Company, Inc.	-	-	-	-	Yes
2/18/2021	Healthmode, Inc.	-	Mind Medicine (MindMed) Inc. (OTCPK:MMEF)	\$33.2	-	-	-	No
2/18/2021	DDS Lab LLC	Trustar Capital; Blue Sea Capital LLC	RoundTable Healthcare Management, LLC	-	-	-	-	Yes
2/18/2021	Beacon Discovery, Inc.	-	Eurofins Scientific SE (ENXTPA:ERF)	-	-	-	-	No
2/18/2021	Venice Family Clinic	-	South Bay Family Health Care Center Inc.	-	-	-	-	No
2/18/2021	LUMEDX Corporation	-	Intelrad Medical Systems Incorporated	-	-	-	-	No
2/18/2021	Night-Light After Hours Pediatrics, P.A.	-	MEDNAX, Inc. (NYSE:MD)	-	-	-	-	No
2/18/2021	Behavior Analysis Center For Autism	-	Learn-it Systems, LLC	-	-	-	-	No
2/17/2021	Targeted Pharmaceuticals, LLC	-	Tetra Bio-Pharma Inc. (TSX:TBP)	\$11.6	-	-	-	No
2/17/2021	Cognate BioServices, Inc.	Essex Woodlands Management, Inc.; Tennenbaum Capital Partners, LLC; Medivate Partners LLC; BlackRock TCP Capital Corp. (NasdaqGS:TCPC)	Charles River Laboratories International, Inc. (NYSE:CRL)	\$875.0	-	-	-	No
2/17/2021	Artemis Institute for Clinical Research, LLC	-	Headlands Research	-	-	-	-	Yes
2/17/2021	Cell sorting technology assets of Propel Labs, Inc.	Propel Labs, Inc.	Thermo Fisher Scientific Inc. (NYSE:TMO)	-	-	-	-	No
2/17/2021	Redemption Recovery Center LLC	-	AppleGate Recovery LLC	-	-	-	-	No
2/17/2021	Total Access Urgent Care P.C.	-	ICV Partners, LLC	-	-	-	-	Yes
2/17/2021	MedPilot Inc.	Plymouth Growth Partners; North Coast Ventures; Techstars Central LLC; Plug and Play, LLC; JumpStart Inc.; Blueprint Health; Hudson River Capital Partners; Valley Growth Ventures, LLC; Fuchs Ventures, LLC; Wavemaker Three-Sixty Health; The Cedars-Sinai Accelerator	Vytalize Health	-	-	-	-	Yes
2/17/2021	Reference Genomics, Inc.	Y Combinator Management LLC	Invitae Corporation (NYSE:NVTA)	\$75.9	-	-	-	Yes
2/16/2021	Ad-Tech Medical Instrument Corporation	-	ArchiMed SAS	-	-	-	-	Yes
2/16/2021	Physmed, Incorporated/Serene Care Hospice	-	Charter Health Care Group, LLC	-	-	-	-	No
2/16/2021	T/Pump Product Line of Stryker Corporation	Stryker Corporation (NYSE:SYK)	Critical Care Diagnostics, Inc.	-	-	-	-	No
2/16/2021	Born Inc.	-	Born Inc. (OTCPK:BRRN)	-	-	-	-	No
2/16/2021	Vetter Software, Inc.	-	DaySmart Software, Inc.	-	-	-	-	No
2/16/2021	Performance Physical Therapy, Inc.	-	Physical Rehabilitation Network, LLC	-	-	-	-	No
2/16/2021	Ashion Analytics, LLC	PMed Management, LLC	Exact Sciences Corporation (NasdaqCM:EXAS)	\$141.5	-	-	-	No
2/16/2021	Four dispensaries of Verdant Creations	Verdant Creations LLC	Cresco Labs Inc. (CNSX:CL)	-	-	-	-	No
2/16/2021	rfxcel Corporation	Kayne Anderson Capital Advisors, L.P.	Antares Vision, Inc.	\$150.0	8.8x	-	-	Yes
2/16/2021	DB Labs, LLC	-	Kaycha Holdings LLC	-	-	-	-	No
2/16/2021	Markley Rehabilitation & Healthcare Center	-	Tryko Partners, LLC	-	-	-	-	Yes

What We've Been Reading

PAYORS | PAYORS ARE ERECTING HIGHER HURDLES TO CARE: HOW CAN HOSPITALS CLEAR THEM?

If you haven't paid attention to the financial health of large insurers during the pandemic, it's never been better. Unfortunately, the same cannot be said of hospitals and patients. Both are struggling to hurdle escalating barriers to scheduled care due to prior authorization requirements. While prior authorizations are intended to reduce "unnecessary" procedures, they result in multiple burdens on providers and patients. No-auth denials are the first financial impact, and these can be as high as 10% of a provider's net revenue. To offset these losses providers must often bill unsuspecting patients who are not prepared for the surprise bill for a covered procedure. Providers expend a massive amount of time, effort and cost into denials management as well as prevention strategies, including a dedicated team of authorization experts who attempt to stem the tide prior to service, with faxes, phone calls and web portals. This herculean effort is incredibly complex, arcane, expensive and often ineffective. In a recent white paper, the American Hospital Association claims the main purpose of these administrative barriers is to restrict access and inappropriately withhold reimbursement. Prior authorization was required for more procedures than ever in 2020, and the trend shows no signs of slowing. And why would it? It works. But beyond the financial distress on hospitals and patients, prior authorization also can lead to poor patient outcomes. Nearly one in four physicians surveyed said prior authorization requirements led to a serious adverse patient event.

[Read the article.](#)

PROVIDER | AMAZON CARE, INTERMOUNTAIN FORM COALITION TO PUSH FOR CMS HOME CARE REIMBURSEMENT CHANGES

Home-based care companies, including Amazon Care and two health systems, are lobbying Congress to make permanent changes to home health care reimbursement policies. Intermountain Healthcare and Ascension are two of the founding members of the Moving Health Home coalition, which aims to change the way policymakers think about the home as a site of clinical service. The COVID-19 pandemic exposed the untapped potential of home-based clinical care and the opportunity for a more robust set of services ranging from primary care to hospital-level treatment, the coalition said in a press release. "The advent of telehealth, remote monitoring, digital therapeutics, provider home visiting, medical records sharing, and other technology has shown that care in the home can be at least equivalent to, if not better than, care offered in facilities," the organizations said. Other members of the coalition are home-based providers Amazon Care, Landmark Health, Signify Health, Dispatch Health, Elara Caring and Home Instead. In 2019, Amazon announced it was piloting a new virtual health service benefit for employees and their families in the Seattle region called Amazon Care. The tech giant said the service combines "the best of both virtual and in-person care" by offering virtual visits, in-person primary care visits at patients' homes or offices, and prescription delivery. Moving Health Home says it has five policy priorities, and top of the list is pushing for Medicare coverage of higher-acuity home-based services, such as emergency services. The group also wants policymakers to create an extended care benefit that would serve as a home-based alternative for skilled nursing facility care. The coalition also is advocating for permanent "Hospital without Walls" site-of-care flexibility to support home-based hospital services. The coalition also wants home-based evaluation and monitoring services to be reimbursed at the same rate as the 2022 Medicare Physician Fee Schedule for what primary care office visits are paid.

[Read the article.](#)

PROVIDER | ONE-SIZE-FITS-ALL ADDICTION TREATMENT MUST BE REPLACED

It's hard to overstate the lasting downstream impact of COVID-19 on substance use disorder (SUD). Already deemed a public health crisis in 2016 by then-Surgeon General Vivek Murthy, the affect stemming from months of social isolation, fear and economic despair is on track to be devastating without a dramatic shift in treatment and payment models. To date, discussions about how to "fix" this crisis and repair the addiction treatment landscape centered around crucial pieces to the puzzle, namely increased access via telemedicine and removing the "X waiver," a widely condemned federal regulation that requires providers to obtain this waiver in order to prescribe buprenorphine to patients who suffer from opioid use disorder. Realizing these two improvements would bring near immeasurable positive results, saving countless lives and changing the addiction care system for the better. However, one major piece to the puzzle still remains – measurement. More specifically, measurement of disease progression, treatment efficacy and long-term outcomes. Such an instrument would lead to a virtuous cycle, positively impacting downstream effects like quality of care, cost, and better treatment modalities and therapeutics. SUD is a brain disease, the result of the complex interactions between an individual's biology, psychology and socio-environmental factors (otherwise known as the biopsychosocial framework). While addiction treatment has traditionally focused on the removal of substance use "symptoms" by collecting urine samples and screening for substance use, the complexity of the biopsychosocial framework requires commensurate measurement tooling.

[Read the article.](#)

CONTENTS

- › PUBLIC MARKETS OVERVIEW
- › EQUITY MARKETS OVERVIEW
- › M&A OVERVIEW
- › DEBT MARKETS OVERVIEW
- › HEALTHCARE & LIFE SCIENCES PUBLIC COMPARABLES
- › M&A TRANSACTIONS

CONTACTS

Turner Bredrup
Senior Advisor
tbredrup@harriswilliams.com
+1 (804) 915-0110

James Clark
Managing Director
jclark@harriswilliams.com
+1 (804) 915-0119

Andy Dixon
Managing Director
adixon@harriswilliams.com
+1 (415) 217-3419

Paul Hepper
Managing Director
phepper@harriswilliams.com
+1 (804) 932-1326

Whit Knier
Managing Director
wknier@harriswilliams.com
+1 (804) 932-1321

Cheairs Porter
Managing Director
cporter@harriswilliams.com
+1 (804) 915-0130

Geoff Smith
Managing Director
gsmith@harriswilliams.com
+1 (804) 915-0195

Nick Owens
Director
nowens@harriswilliams.com
+1 (415) 217-3453

Tyler Bradshaw
Director
tbradshaw@harriswilliams.com
+1 (804) 887-6121

Charles Busch
Vice President
cbusch@harriswilliams.com
+1 (804) 887-6093

Andrew Hoft
Vice President
ahoft@harriswilliams.com
+1 (415) 265-6139

Michael Mahoney
Vice President
mmahoney@harriswilliams.com
+1 (415) 217-3452

Nathan Robertson
Vice President
nrobertson@harriswilliams.com
+1 (804) 887-6135

Lucas Scholl
Vice President
lscholl@harriswilliams.com
+1 (415) 416-0766

Taylor Will
Vice President
twill@harriswilliams.com
+1 (804) 887-6068

Public Comparables

Payor, Provider, & Pharmacy Support Services⁽¹⁾

Company Name	Stock Price					Equity Mkt. Value	Total Debt	Cash and Equiv.	Total Ent. Value (TEV)	Latest Twelve Months (LTM)			LTM Period	Latest FYE Date	Forward Twelve Month Estimate			TEV / LTM Multiples		TEV / Fwd Multiples				
	2/28/2021	% Change		52 Week						Revenue	EBITDA	EBIT			Revenue	EBITDA	EBIT	Revenue	EBITDA	EBIT	Revenue	EBITDA	Revenue	EBITDA
	3 mos.	12 mos.	High	Low																				
Clinical Laboratories																								
Laboratory Corporation of America Holdings	\$239.91	20.0%	36.6%	\$252.45	\$98.02	\$23,415	\$6,756	\$1,321	\$28,917	\$13,979	\$3,871	\$3,092	Dec-20	Dec-20	\$14,278	\$3,300	\$2,939	2.1x	7.5x	2.0x	8.8x			
Quest Diagnostics Incorporated	115.59	(7.4%)	9.0%	134.71	73.02	15,426	4,808	1,158	19,372	9,437	2,843	2,182	Dec-20	Dec-20	9,552	2,416	1,923	2.1x	6.8x	2.0x	8.0x			
Number of Companies	2	Median:	6.3%	22.8%	Total	\$38,841			\$48,290	\$23,416					\$23,830			2.1x	7.1x	2.0x	8.4x			
Market Cap. Weighted Average:			9.1%	25.6%														2.1x	7.2x	2.0x	8.5x			
Contract Pharma Manufacturing																								
Cleantech Building Materials Plc	\$3.63	0.0%	0.0%	\$0.00	\$0.00	\$264	\$1	\$0	\$274	\$1	(\$3)	(\$4)	Jun-20	Dec-19	NA	NA	NA	NM	NM	NA	NA			
West Pharmaceutical Services, Inc.	280.65	1.0%	86.4%	312.12	124.53	20,797	331	616	20,997	2,147	564	438	Dec-20	Dec-20	2,542	693	571	9.8x	NM	8.3x	30.3x			
Number of Companies	2	Median:	0.5%	43.2%	Total	\$21,061			\$21,270	\$2,148					\$2,542			9.8x	#NUM!	8.3x	30.3x			
Market Cap. Weighted Average:			1.0%	85.3%														9.8x	NM	8.3x	30.3x			
Contract Research Organizations																								
Catalent, Inc.	\$113.71	16.7%	120.7%	\$127.68	\$31.04	\$19,356	\$3,060	\$833	\$21,942	\$3,465	\$787	\$516	Dec-20	Jun-20	\$4,119	\$1,080	\$850	6.3x	27.9x	5.3x	20.3x			
Charles River Laboratories International, Inc.	286.14	24.3%	83.9%	303.79	95.58	14,243	2,160	229	16,393	2,924	815	541	Dec-20	Dec-20	3,380	835	685	5.6x	20.1x	4.8x	19.6x			
ICON Public Limited Company	180.68	(5.5%)	15.8%	223.62	104.28	9,538	434	842	9,169	2,797	505	409	Dec-20	Dec-20	3,247	587	518	3.3x	18.1x	2.8x	15.6x			
Syneos Health, Inc.	77.35	16.0%	22.1%	81.35	30.02	8,068	3,237	272	11,065	4,416	665	357	Dec-20	Dec-20	5,226	766	688	2.5x	16.6x	2.1x	14.4x			
PRA Health Sciences, Inc.	147.41	32.8%	56.5%	155.00	58.67	9,514	1,474	506	10,793	3,183	469	284	Dec-20	Dec-20	3,598	600	537	3.4x	23.0x	3.0x	18.0x			
IQVIA Holdings Inc.	192.79	14.2%	38.2%	199.99	81.79	36,971	13,238	1,902	49,020	11,359	2,046	817	Dec-20	Dec-20	12,793	2,802	2,404	4.3x	24.0x	3.8x	17.5x			
Number of Companies	6	Median:	16.4%	47.3%	Total	\$97,690			\$118,382	\$28,144					\$32,363			3.9x	21.6x	3.4x	17.7x			
Market Cap. Weighted Average:			16.2%	59.5%														4.6x	22.9x	4.0x	18.0x			
Disease Management																								
Tivity Health, Inc.	\$23.80	34.2%	87.8%	\$25.45	\$1.92	\$1,166	\$523	\$100	\$1,589	\$438	\$145	\$132	Dec-20	Dec-20	\$488	\$153	\$135	3.6x	11.0x	3.3x	10.4x			
Number of Companies	1	Median:	34.2%	87.8%	Total	\$1,166			\$1,589	\$438					\$488			3.6x	11.0x	3.3x	10.4x			
Market Cap. Weighted Average:			34.2%	87.8%														3.6x	11.0x	3.3x	10.4x			
Healthcare Staffing																								
AMN Healthcare Services, Inc.	\$72.87	9.5%	(1.0%)	\$89.22	\$36.65	\$3,438	\$955	\$29	\$4,364	\$2,394	\$291	\$166	Dec-20	Dec-20	\$2,805	\$379	\$265	1.8x	15.0x	1.6x	11.5x			
Cross Country Healthcare, Inc.	11.11	18.3%	17.2%	13.42	4.50	417	78	2	494	836	38	16	Dec-20	Dec-20	920	44	32	0.6x	13.0x	0.5x	11.1x			
ASGN Incorporated	92.97	15.6%	83.3%	100.97	29.04	4,918	1,126	274	5,677	3,951	446	310	Dec-20	Dec-20	4,227	467	349	1.4x	12.7x	1.3x	12.2x			
Number of Companies	3	Median:	15.6%	17.2%	Total	\$8,773			\$10,535	\$7,181					\$7,952			1.4x	13.0x	1.3x	11.5x			
Market Cap. Weighted Average:			13.3%	47.1%														1.5x	13.6x	1.3x	11.9x			

Public Comparables

Payor, Provider, & Pharmacy Support Services⁽¹⁾

Company Name	Stock Price					Equity Mkt. Value	Total Debt	Cash and Equiv.	Total Ent. Value (TEV)	Latest Twelve Months (LTM)			LTM Period	Latest FYE Date	Forward Twelve Month Estimate			TEV/ LTM Multiples		TEV/ Fwd Multiples				
	2/28/2021	% Change		52 Week						Revenue	EBITDA	EBIT			Revenue	EBITDA	EBIT	Revenue	EBITDA	EBIT	Revenue	EBITDA	Revenue	EBITDA
		3 mos.	12 mos.	High	Low																			
HMO - Medical																								
Commercial:																								
Anthem, Inc.	303.19	(3.1%)	17.9%	340.98	171.03	74,253	20,992	30,733	90,251	121,868	9,481	8,260	Dec-20	Dec-20	135,407	9,193	8,268	0.7x	9.5x	0.7x	9.8x			
Cigna Corporation	209.90	(1.2%)	14.7%	230.90	118.50	73,852	33,562	11,500	97,858	160,550	10,940	8,899	Dec-20	Dec-20	165,695	11,147	8,536	0.6x	8.9x	0.6x	8.8x			
Humana Inc.	379.65	(6.6%)	18.8%	474.70	208.25	48,922	7,464	17,227	51,736	77,155	5,522	5,060	Dec-20	Dec-20	81,927	4,266	3,762	0.7x	9.4x	0.6x	12.1x			
UnitedHealth Group Incorporated	332.22	(1.7%)	30.3%	367.95	187.72	315,217	47,914	19,781	349,293	257,141	25,582	22,405	Dec-20	Dec-20	279,075	26,219	23,086	1.4x	13.7x	1.3x	13.3x			
Number of Companies	4	Median:	(2.4%)	18.3%	Total	\$512,245			\$589,138	\$616,714					\$662,104			0.7x	9.4x	0.6x	11.0x			
Market Cap. Weighted Average:		(2.3%)	25.2%															1.1x	12.0x	1.0x	12.0x			
Government:																								
Centene Corporation	\$58.54	(7.3%)	10.4%	\$74.70	\$43.96	\$34,046	\$18,317	\$12,380	\$41,752	\$104,176	\$5,710	\$4,110	Dec-20	Dec-20	\$117,744	\$5,103	\$4,320	0.4x	7.3x	0.4x	8.2x			
Molina Healthcare, Inc.	216.76	4.7%	76.9%	246.72	102.85	12,572	2,440	6,029	10,920	18,375	1,050	972	Dec-20	Dec-20	24,443	1,187	1,075	0.6x	10.4x	0.4x	9.2x			
Webcentral Group Limited	0.44	65.2%	395.7%	0.50	0.05	68	43	3	109	40	(10)	(17)	Dec-20	Dec-20	51	7	1	2.7x	NM	2.1x	16.6x			
Number of Companies	3	Median:	4.7%	76.9%	Total	\$46,687			\$52,781	\$122,591					\$142,238			0.6x	8.9x	0.4x	9.2x			
Market Cap. Weighted Average:		(4.0%)	28.9%															0.5x	8.1x	0.4x	8.5x			
Information Services																								
Data/Analytics:																								
Castlight Health, Inc.	\$1.70	40.5%	87.6%	\$2.15	\$0.60	\$268	\$15	\$49	\$233	\$147	(\$1)	(\$12)	Dec-20	Dec-20	\$133	\$4	(\$5)	1.6x	NM	1.8x	NM			
Inovalon Holdings, Inc.	24.56	29.1%	26.1%	28.75	13.39	3,815	1,034	124	4,730	668	201	75	Dec-20	Dec-20	756	271	119	7.1x	23.6x	6.3x	17.4x			
National Research Corporation	51.67	(3.2%)	(6.0%)	60.62	34.00	1,312	33	35	1,329	133	50	43	Dec-20	Dec-20	NA	NA	NA	10.0x	26.4x	NA	NA			
Number of Companies	3	Median:	29.1%	26.1%	Total	\$5,394			\$1,329	\$948					\$889			7.1x	25.0x	4.0x	17.4x			
Market Cap. Weighted Average:		21.8%	21.3%															7.5x	24.3x	6.0x	17.4x			
Hospital/Physician:																								
Allscripts Healthcare Solutions, Inc.	\$15.43	8.6%	104.6%	\$17.96	\$4.56	\$2,161	\$283	\$531	\$1,940	\$1,503	\$43	(\$39)	Dec-20	Dec-20	\$1,512	\$244	\$133	1.3x	NM	1.3x	7.9x			
Cerner Corporation	69.14	(6.7%)	(0.2%)	84.20	53.08	21,177	1,493	1,058	21,720	5,506	1,318	831	Dec-20	Dec-20	5,817	1,873	1,198	3.9x	16.5x	3.7x	11.6x			
Computer Programs and Systems, Inc.	31.45	8.7%	17.4%	36.37	16.93	442	82	13	511	264	36	21	Dec-20	Dec-20	274	47	26	1.9x	14.2x	1.9x	10.8x			
HMS Holdings Corp.	36.79	14.6%	60.1%	37.04	18.20	3,261	259	207	3,351	673	138	93	Dec-20	Dec-20	738	208	129	5.0x	24.3x	4.5x	16.1x			
Premier, Inc.	33.82	(4.7%)	14.9%	37.79	27.11	4,134	612	109	4,646	1,447	484	334	Dec-20	Jun-20	1,570	462	284	3.2x	9.6x	3.0x	10.0x			
NextGen Healthcare, Inc.	18.70	3.9%	43.0%	23.80	5.10	1,253	71	90	1,246	549	41	19	Dec-20	Mar-20	570	113	32	2.3x	30.2x	2.2x	11.0x			
Number of Companies	6	Median:	6.2%	30.2%	Total	\$32,427			\$33,414	\$9,943					\$10,480			2.7x	16.5x	2.6x	10.9x			
Market Cap. Weighted Average:		(2.7%)	16.7%															3.7x	16.9x	3.5x	11.6x			

Public Comparables

Payor, Provider, & Pharmacy Support Services⁽¹⁾

Company Name	Stock Price					Equity Mkt. Value	Total Debt	Cash and Equiv.	Total Ent. Value (TEV)	Latest Twelve Months (LTM)			LTM Period	Latest FYE Date	Forward Twelve Month Estimate			TEV/ LTM Multiples		TEV/ Fwd Multiples			
	2/28/2021	% Change		52 Week						Revenue	EBITDA	EBIT			Revenue	EBITDA	EBIT	Revenue	EBITDA	Revenue	EBITDA	Revenue	EBITDA
		3 mos.	12 mos.	High	Low																		
<i>Specialty Managed Care</i>																							
Assurant, Inc.	\$123.22	(7.9%)	2.2%	\$143.67	\$76.27	\$7,135	\$2,331	\$2,562	\$7,243	\$10,089	\$956	\$784	Dec-20	Dec-20	\$9,063	NA	\$960	0.7x	7.6x	0.8x	NA		
CorVel Corporation	101.50	10.9%	47.2%	110.80	44.67	1,815	96	129	1,822	554	94	55	Dec-20	Mar-20	NA	NA	NA	3.3x	19.4x	NA	NA		
HealthEquity, Inc.	82.35	13.6%	16.0%	93.32	34.40	6,767	1,092	299	7,654	747	233	107	Oct-20	Jan-20	743	237	56	10.3x	32.9x	10.3x	32.4x		
Number of Companies	3	Median:	10.9%	16.0%	Total	\$15,716			\$16,719	\$11,390					\$9,806			3.3x	19.4x	5.5x	32.4x		
Market Cap. Weighted Average:			3.5%	13.3%														5.1x	19.8x	5.4x	32.4x		
<i>Retail Pharmacy</i>																							
CVS Health Corporation	\$68.13	0.4%	15.1%	\$77.23	\$52.04	\$89,343	\$85,042	\$10,854	\$163,843	\$267,908	\$21,340	\$13,663	Dec-20	Dec-20	\$279,580	\$18,048	\$15,685	0.6x	7.7x	0.6x	9.1x		
Walgreens Boots Alliance, Inc.	47.93	22.9%	4.7%	55.49	33.36	41,414	41,881	1,111	82,868	141,505	7,748	1,904	Nov-20	Aug-20	145,179	6,935	5,276	0.6x	10.7x	0.6x	11.9x		
Rite Aid Corporation	19.58	48.3%	43.8%	32.48	8.86	1,081	6,391	51	7,421	23,854	1,418	287	Nov-20	Feb-20	24,234	504	118	0.3x	5.2x	0.3x	14.7x		
Number of Companies	3	Median:	22.9%	15.1%	Total	\$131,837			\$254,131	\$433,267					\$448,993			0.6x	7.7x	0.6x	11.9x		
Market Cap. Weighted Average:			7.8%	12.1%														0.6x	8.6x	0.6x	10.0x		

Public Comparables

Products & Devices⁽¹⁾

Company Name	Stock Price					Equity Mkt. Value	Total Debt	Cash and Equiv.	Total Ent. Value (TEV)	Latest Twelve Months (LTM)			LTM Period	Latest FYE Date	Forward Twelve Month Estimate			TEV / LTM Multiples		TEV / Fwd Multiples			
	2/28/2021	% Change	12 mos.	52 Week						Revenue	EBITDA	EBIT			Revenue	EBITDA	EBIT	Revenue	EBITDA	Revenue	EBITDA	Revenue	EBITDA
		3 mos.	High	Low																			
Dental Products																							
3M Company	\$175.06	(1.0%)	17.3%	\$187.27	\$114.04	\$101,377	\$19,775	\$5,045	\$116,838	\$32,184	\$9,427	\$7,067	Dec-20	Dec-20	\$34,383	\$9,421	\$7,514	3.6x	12.4x	3.4x	12.4x		
DENTSPLY SIRONA Inc.	53.07	2.7%	7.8%	60.47	31.58	11,599	2,455	471	12,677	3,342	672	271	Dec-20	Dec-20	3,820	863	708	3.8x	18.9x	3.3x	14.7x		
Number of Companies	2	Median:	0.8%	12.5%	Total	\$112,976			\$129,515	\$35,526					\$38,204			3.7x	15.6x	3.4x	13.5x		
Market Cap. Weighted Average:			(0.6%)	16.3%														3.6x	13.1x	3.4x	12.6x		
Durable Medical Equipment																							
Arjo AB (publ)	\$7.29	1.4%	26.3%	\$8.29	\$4.52	\$1,985	\$755	\$120	\$2,604	\$1,105	\$233	\$115	Dec-20	Dec-20	\$1,071	\$232	\$116	2.4x	11.2x	2.4x	11.2x		
Hill-Rom Holdings, Inc.	106.67	11.5%	11.1%	117.68	72.29	7,079	1,907	295	8,710	2,937	588	417	Dec-20	Sep-20	2,917	622	546	3.0x	14.8x	3.0x	14.0x		
Invacare Corporation	9.10	3.4%	20.1%	10.94	3.90	313	327	105	534	851	35	8	Dec-20	Dec-20	910	44	26	0.6x	15.4x	0.6x	12.3x		
ResMed Inc.	192.78	(8.0%)	21.3%	224.43	108.85	28,051	966	256	28,872	3,092	1,025	880	Dec-20	Jun-20	3,294	1,093	915	9.3x	28.2x	8.8x	26.4x		
Number of Companies	4	Median:	2.4%	20.7%	Total	\$37,428			\$40,721	\$7,985					\$8,192			2.7x	15.1x	2.7x	13.1x		
Market Cap. Weighted Average:			(3.8%)	19.6%														7.7x	24.6x	7.3x	23.1x		
Life Sciences Tools																							
Agilent Technologies, Inc.	\$122.07	7.0%	58.4%	\$136.98	\$61.13	\$37,279	\$2,675	\$1,329	\$38,523	\$5,530	\$1,517	\$1,151	Jan-21	Oct-20	\$6,002	\$1,611	\$1,484	7.0x	25.4x	6.4x	23.9x		
Becton, Dickinson and Company	241.15	5.3%	1.4%	284.97	197.75	70,069	17,819	3,265	85,093	18,207	5,438	3,259	Dec-20	Sep-20	19,102	5,433	4,565	4.7x	15.6x	4.5x	15.7x		
Thermo Fisher Scientific Inc.	450.08	(0.7%)	54.8%	532.57	250.21	177,239	22,591	10,325	190,855	32,218	10,476	7,878	Dec-20	Dec-20	35,483	11,347	10,574	5.9x	18.2x	5.4x	16.8x		
Number of Companies	3	Median:	5.3%	54.8%	Total	\$284,586			\$314,471	\$55,955					\$60,586			5.9x	18.2x	5.4x	16.8x		
Market Cap. Weighted Average:			1.8%	42.1%														5.8x	18.5x	5.3x	17.5x		
Medical Devices and Products																							
Abbott Laboratories	\$119.78	11.3%	55.5%	\$128.54	\$61.61	\$212,194	\$19,890	\$7,148	\$227,009	\$34,608	\$9,209	\$5,553	Dec-20	Dec-20	\$42,318	\$12,285	\$10,940	6.6x	24.7x	5.4x	18.5x		
Baxter International Inc.	77.69	2.3%	(6.9%)	95.19	69.10	39,242	6,804	3,730	42,773	11,673	2,870	1,878	Dec-20	Dec-20	12,510	3,059	2,290	3.7x	14.9x	3.4x	14.0x		
Boston Scientific Corporation	38.78	15.4%	3.7%	42.37	24.10	54,958	9,614	1,734	63,179	9,913	2,344	1,129	Dec-20	Dec-20	11,430	3,381	2,921	6.4x	27.0x	5.5x	18.7x		
Conformis, Inc.	1.01	55.4%	29.6%	1.49	0.50	178	31	29	185	69	(19)	(25)	Dec-20	Dec-20	71	(26)	(27)	2.7x	NM	2.6x	NM		
Danaher Corporation	219.67	1.3%	51.9%	248.86	119.60	156,450	22,178	6,035	175,872	22,284	6,741	4,704	Dec-20	Dec-20	26,144	8,084	5,940	7.9x	26.1x	6.7x	21.8x		
Hologic, Inc.	72.09	3.7%	53.0%	85.00	26.49	18,575	2,814	869	20,650	4,536	2,267	1,893	Dec-20	Sep-20	5,302	2,650	2,588	4.6x	9.1x	3.9x	7.8x		
Johnson & Johnson	158.46	10.0%	17.8%	173.65	109.16	416,541	36,366	25,425	432,308	82,584	27,545	20,014	Jan-21	Jan-21	91,931	33,063	30,008	5.2x	15.7x	4.7x	13.1x		
Medtronic plc	116.97	2.1%	16.2%	120.53	72.13	157,614	30,323	14,640	174,504	27,926	6,312	3,818	Jan-21	Apr-20	32,246	9,900	9,042	6.2x	27.6x	5.4x	17.6x		
Penumbra, Inc.	284.43	25.5%	71.5%	314.22	121.80	10,367	77	265	10,442	560	7	(18)	Dec-20	Dec-20	681	52	29	18.6x	NM	15.3x	NM		
Stryker Corporation	242.69	4.2%	27.3%	250.02	124.54	91,300	14,425	3,024	104,055	14,351	3,885	2,943	Dec-20	Dec-20	16,992	4,772	4,398	7.3x	26.8x	6.1x	21.8x		
Teleflex Incorporated	398.12	7.3%	18.8%	414.72	221.27	18,588	2,625	396	21,051	2,537	688	430	Dec-20	Dec-20	2,821	829	761	8.3x	30.6x	7.5x	25.4x		
Number of Companies	11	Median:	7.3%	27.3%	Total	\$1,176,006			\$1,272,029	\$211,041					\$242,447			6.4x	26.1x	5.4x	18.5x		
Market Cap. Weighted Average:			7.6%	29.2%														6.3x	21.8x	5.4x	16.9x		
Medical / Surgical / Dental Supplies & Distribution																							
AmerisourceBergen Corporation	\$101.22	(1.9%)	20.0%	\$112.88	\$72.06	\$20,720	\$4,589	\$4,891	\$20,688	\$194,546	\$2,790	\$2,253	Dec-20	Sep-20	\$209,040	\$2,772	\$2,471	0.1x	7.4x	0.1x	7.5x		
Cardinal Health, Inc.	51.52	(4.2%)	(1.2%)	59.46	39.05	15,130	6,733	3,737	18,130	156,452	2,747	1,894	Dec-20	Jun-20	165,091	2,900	2,519	0.1x	6.6x	0.1x	6.3x		
Henry Schein, Inc.	61.85	(2.9%)	1.5%	74.89	41.85	8,811	1,002	421	10,357	10,119	851	580	Dec-20	Dec-20	11,596	934	742	1.0x	12.2x	0.9x	11.1x		
McKesson Corporation	169.52	(5.8%)	21.2%	187.67	112.60	26,982	9,714	3,577	34,632	237,621	5,041	3,565	Dec-20	Mar-20	249,128	4,837	4,111	0.1x	6.9x	0.1x	7.2x		
Owens & Minor, Inc.	34.01	36.5%	398.0%	35.73	3.63	2,500	1,197	83	3,614	8,480	394	241	Dec-20	Dec-20	9,326	454	369	0.4x	9.2x	0.4x	8.0x		
Patterson Companies, Inc.	31.06	11.2%	30.6%	36.88	12.93	2,957	795	156	3,624	5,637	356	241	Jan-21	Apr-20	5,899	319	274	0.6x	10.2x	0.6x	11.4x		
Number of Companies	6	Median:	(2.4%)	20.6%	Total	\$77,100			\$91,045	\$612,855					\$650,080			0.3x	8.3x	0.3x	7.7x		
Market Cap. Weighted Average:			(2.1%)	26.8%														0.3x	7.8x	0.2x	7.7x		

Public Comparables

Products & Devices⁽¹⁾

Company Name	Stock Price					Equity Mkt. Value	Total Debt	Cash and Equiv.	Total Ent. Value (TEV)	Latest Twelve Months (LTM)			LTM Period	Latest FYE Date	Forward Twelve Month Estimate			TEV/ LTM Multiples		TEV/ Fwd Multiples			
	2/28/2021	% Change		52 Week						Revenue	EBITDA	EBIT			Revenue	EBITDA	EBIT	Revenue	EBITDA	Revenue	EBITDA	Revenue	EBITDA
		3 mos.	12 mos.	High	Low																		
<i>Spec Pharma and Generics</i>																							
Aegon N.V.	\$4.79	29.4%	28.8%	\$4.97	\$1.88	\$9,674	\$0	\$51,177	(\$40,855)	\$62,751	\$1,300	\$991	Dec-20	Dec-20	\$23,978	NA	\$2,081	NM	NM	NM	NA		
Anneal Pharmaceuticals, Inc.	5.39	32.4%	40.0%	6.18	2.40	796	2,997	343	3,407	1,993	407	146	Dec-20	Dec-20	2,127	503	413	1.7x	8.4x	1.6x	6.8x		
Eagle Pharmaceuticals, Inc.	44.50	(5.9%)	(3.1%)	56.16	33.80	580	38	103	529	188	38	33	Dec-20	Dec-20	206	30	NA	2.8x	14.0x	2.6x	17.4x		
Endo International plc	7.93	47.1%	43.7%	10.89	2.08	1,828	8,396	1,213	9,010	2,903	814	694	Dec-20	Dec-20	2,703	1,236	1,121	3.1x	11.1x	3.3x	7.3x		
Horizon Therapeutics Public Limited Company	90.91	28.9%	165.7%	96.54	23.81	20,368	1,051	2,080	19,836	2,200	561	530	Dec-20	Dec-20	2,781	1,106	1,062	9.0x	NM	7.1x	17.9x		
Jazz Pharmaceuticals plc	168.04	17.3%	46.7%	178.64	86.88	9,465	2,252	2,133	9,847	2,364	1,066	763	Dec-20	Dec-20	2,590	1,212	1,139	4.2x	9.2x	3.8x	8.1x		
Lannett Company, Inc.	6.06	(5.2%)	(30.3%)	10.70	4.89	243	629	34	838	543	73	12	Dec-20	Jun-20	476	71	41	1.5x	11.5x	1.8x	11.7x		
Minerals Technologies Inc.	71.39	13.5%	45.3%	73.20	31.46	2,411	1,003	372	0	1,595	320	211	Dec-20	Dec-20	1,738	335	240	0.0x	0.0x	0.0x	0.0x		
Myanmar Metals Limited	0.05	(6.7%)	75.0%	0.09	0.02	103	0	8	94	0	(10)	(10)	Jun-20	Jun-20	NA	NA	NA	NA	NM	NA	NA		
Perrigo Company plc	40.36	(16.0%)	(20.4%)	58.83	38.20	5,509	3,759	644	8,355	5,063	912	479	Dec-20	Dec-20	5,118	897	808	1.7x	9.2x	1.6x	9.3x		
Teva Pharmaceutical Industries Limited	10.76	9.6%	(6.7%)	13.30	6.25	11,798	26,535	2,177	37,191	16,659	4,905	3,193	Dec-20	Dec-20	16,702	5,012	4,432	2.2x	7.6x	2.2x	7.4x		
Bausch Health Companies Inc.	31.42	60.9%	42.0%	32.50	11.15	11,174	24,204	605	34,893	8,027	3,236	1,334	Dec-20	Dec-20	8,693	3,461	3,160	4.3x	10.8x	4.0x	10.1x		
Number of Companies	12	Median:		15.4%	41.0%	Total	\$73,948		\$83,146	\$104,285					\$67,112			2.5x	9.2x	2.4x	8.7x		
Market Cap. Weighted Average:		25.4%	62.1%															4.9x	8.8x	4.2x	11.3x		

Public Comparables

Provider-Based Services⁽¹⁾

Company Name	Stock Price					Equity Mkt. Value	Total Debt	Cash and Equiv.	Total Ent. Value (TEV)	Latest Twelve Months (LTM)			LTM Period	Latest FYE Date	Forward Twelve Month Estimate			TEV/ LTM Multiples		TEV/ Fwd Multiples			
	2/28/2021	% Change	52 Week		Revenue					EBITDA	EBIT	Revenue			EBITDA	EBIT	Revenue	EBITDA	EBIT	Revenue	EBITDA	Revenue	EBITDA
	3 mos.	12 mos.	High	Low																			
Acute-Care Hospitals																							
Community Health Systems, Inc.	\$8.56	1.9%	73.6%	\$11.45	\$2.25	\$1,071	\$12,882	\$1,676	\$12,848	\$11,789	\$1,348	\$586	Dec-20	Dec-20	\$12,063	\$1,650	\$1,128	1.1x	9.5x	1.1x	7.8x		
HCA Healthcare, Inc.	172.03	12.4%	35.4%	181.01	58.38	58,476	33,102	1,909	91,989	51,533	10,900	7,256	Dec-20	Dec-20	54,542	10,652	7,829	1.8x	8.4x	1.7x	8.6x		
Tenet Healthcare Corporation	51.02	55.2%	94.1%	53.80	10.00	5,418	16,906	2,446	22,762	17,640	2,999	1,739	Dec-20	Dec-20	19,396	2,996	2,129	1.3x	7.6x	1.2x	7.6x		
Number of Companies	3	Median:	12.4%	73.6%	Total	\$64,965			\$127,599	\$80,962					\$86,001			1.3x	8.4x	1.2x	7.8x		
Market Cap. Weighted Average:			15.8%	41.0%														1.7x	8.4x	1.6x	8.5x		
Assisted Living																							
Brookdale Senior Living Inc.	\$5.82	31.4%	(11.4%)	\$6.65	\$1.47	\$1,068	\$5,445	\$553	\$5,962	\$3,023	\$631	\$28	Dec-20	Dec-20	\$3,151	\$273	(\$77)	2.0x	9.5x	1.9x	21.8x		
Capital Senior Living Corporation	31.28	122.6%	(18.5%)	41.36	6.75	64	925	14	975	397	84	(25)	Sep-20	Dec-19	NA	NA	NA	2.5x	11.6x	NA	NA		
Number of Companies	2	Median:	77.0%	(15.0%)	Total	\$1,132			\$6,937	\$3,420					\$3,151			2.2x	10.5x	1.9x	21.8x		
Market Cap. Weighted Average:			36.5%	(11.8%)														2.0x	9.6x	1.9x	21.8x		
Long-Term Care																							
National HealthCare Corporation	69.55	7.4%	(6.3%)	80.51	55.88	1,069	194	323	943	978	127	44	Dec-20	Dec-20	NA	NA	NA	1.0x	7.5x	NA	NA		
The Ensign Group, Inc.	82.02	14.6%	84.3%	92.39	24.06	4,438	1,114	250	5,521	2,403	419	223	Dec-20	Dec-20	2,654	329	268	2.3x	13.2x	2.1x	16.8x		
Number of Companies	2	Median:	11.0%	39.0%	Total	\$5,507			\$6,465	\$3,381					\$2,654			1.6x	10.3x	2.1x	16.8x		
Market Cap. Weighted Average:			13.2%	66.7%														2.0x	12.1x	2.1x	16.8x		
Diagnostic Imaging																							
RadNet, Inc.	\$18.44	(3.7%)	(9.7%)	\$22.32	\$5.81	\$952	\$1,185	\$102	\$2,130	\$1,098	\$247	\$53	Dec-20	Dec-20	\$1,214	\$177	\$82	1.9x	8.6x	1.8x	12.0x		
Varian Medical Systems, Inc.	175.27	0.8%	42.5%	176.50	89.62	16,097	351	773	15,761	3,118	573	425	Jan-21	Oct-20	3,583	754	646	5.1x	27.5x	4.4x	20.9x		
Number of Companies	2	Median:	(1.5%)	16.4%	Total	\$17,049			\$17,891	\$4,216					\$4,796			3.5x	18.1x	3.1x	16.5x		
Market Cap. Weighted Average:			0.5%	39.6%														4.9x	26.5x	4.3x	20.4x		
Dialysis Services																							
Ariadne Australia Limited	\$0.37	(5.9%)	(18.6%)	\$0.46	\$0.29	\$73	\$17	\$24	\$76	\$7	\$4	\$1	Dec-20	Jun-20	NA	NA	NA	11.3x	19.2x	NA	NA		
DaVita Inc.	102.13	(7.1%)	31.6%	125.28	62.20	11,173	11,194	345	23,846	11,551	3,040	1,746	Dec-20	Dec-20	11,553	2,394	1,753	2.1x	7.8x	2.1x	10.0x		
Fresenius Medical Care AG & Co. KGaA	69.40	(19.0%)	(17.3%)	96.75	64.73	20,326	15,144	1,542	35,136	21,846	4,875	2,987	Dec-20	Dec-20	21,745	4,548	2,438	1.6x	7.2x	1.6x	7.7x		
Number of Companies	3	Median:	(7.1%)	(17.3%)	Total	\$31,572			\$59,058	\$33,403					\$33,299			2.1x	7.8x	1.8x	8.8x		
Market Cap. Weighted Average:			(14.7%)	2.9%														1.8x	7.5x	1.8x	8.5x		
Home Care, Hospice, and Home Infusion																							
Home Care / Hospice:																							
Addus HomeCare Corporation	\$107.57	11.8%	41.0%	\$129.01	\$43.13	\$1,685	\$240	\$145	\$1,815	\$765	\$73	\$51	Dec-20	Dec-20	\$868	\$92	\$73	2.4x	24.9x	2.1x	19.7x		
Amedisys, Inc.	253.64	5.4%	45.8%	325.12	132.95	8,332	307	82	8,598	2,072	288	218	Dec-20	Dec-20	2,305	322	290	4.2x	29.8x	3.7x	26.7x		
Chemed Corporation	445.21	(6.0%)	6.6%	560.00	330.01	7,102	135	163	7,185	2,080	426	315	Dec-20	Dec-20	2,066	423	354	3.5x	16.9x	3.5x	17.0x		
LHC Group, Inc.	181.71	(8.4%)	49.6%	236.81	100.00	5,741	123	287	5,691	2,063	257	180	Dec-20	Dec-20	2,239	279	NA	2.8x	22.2x	2.5x	20.4x		
Number of Companies	4	Median:	(0.3%)	43.4%	Total	\$22,859			\$23,290	\$6,979					\$7,477			3.1x	23.5x	3.0x	20.1x		
Market Cap. Weighted Average:			(1.1%)	1.4%														3.5x	23.5x	3.2x	21.6x		
Home Infusion:																							
Bioservo Technologies AB (publ)	\$1.70	33.6%	9.2%	\$2.22	\$0.76	\$27	\$0	\$6	\$21	\$1	(\$3)	(\$4)	Dec-20	Dec-20	NA	NA	NA	14.5x	NM	NA	NA		
Number of Companies	1	Median:	33.6%	9.2%	Total	\$27			\$21	\$1					\$0			14.5x	NM	NM	NM		
Market Cap. Weighted Average:			33.6%	9.2%														14.5x	NM	NM	NM		

Public Comparables

Provider-Based Services⁽¹⁾

Company Name	Stock Price					Equity Mkt. Value	Total Debt	Cash and Equiv.	Total Ent. Value (TEV)	Latest Twelve Months (LTM)			LTM Period	Latest FYE Date	Forward Twelve Month Estimate			TEV/ LTM Multiples		TEV/ Fwd Multiples	
	2/28/2021	% Change	12 mos.	52 Week						Revenue	EBITDA	EBIT			Revenue	EBITDA	EBIT	Revenue	EBITDA	Revenue	EBITDA
Physician Practice Management																					
Specialty:																					
MEDNAX, Inc.	\$24.43	21.5%	42.9%	\$29.26	\$7.37	\$2,062	\$1,805	\$1,229	\$2,646	\$1,734	\$232	\$174	Dec-20	Dec-20	\$1,771	\$231	\$187	1.5x	11.4x	1.5x	11.4x
Number of Companies	1	Median:	21.5%	42.9%	Total	\$2,062			\$2,646	\$1,734					\$1,771			1.5x	11.4x	1.5x	11.4x
Market Cap. Weighted Average:			21.5%	42.9%														1.5x	11.4x	1.5x	11.4x
Behavioral Health / Management																					
Australian Agricultural Company Limited	\$0.87	(1.3%)	2.3%	\$0.94	\$0.73	\$523	\$286	\$10	\$820	\$212	(\$106)	(\$119)	Sep-20	Mar-20	\$193	\$15	\$5	3.9x	NM	4.3x	NM
Acadia Healthcare Company, Inc.	55.24	27.9%	86.6%	57.03	11.09	4,919	3,268	379	7,890	2,090	465	333	Dec-20	Dec-20	2,274	506	383	3.8x	17.0x	3.5x	15.6x
Civitas Solutions, Inc.	0.00	0.0%	0.0%	0.00	0.00	0	706	10	0	1,613	173	83	Dec-18	Sep-18	NA	NA	NA	0.0x	0.0x	NA	NA
Magellan Health, Inc.	93.32	15.3%	55.5%	95.43	30.60	2,423	678	1,147	2,005	4,578	97	22	Dec-20	Dec-20	4,651	230	124	0.4x	20.7x	0.4x	8.7x
Universal Health Services, Inc.	125.33	(5.1%)	1.3%	143.84	65.20	10,664	4,194	1,224	13,854	11,559	1,987	1,360	Dec-20	Dec-20	12,103	1,836	1,314	1.2x	7.0x	1.1x	7.5x
Number of Companies	5	Median:	0.0%	2.3%	Total	\$18,529			\$24,570	\$20,051					\$19,221			1.2x	12.0x	2.3x	8.7x
Market Cap. Weighted Average:			6.4%	31.1%														1.9x	11.5x	1.8x	9.9x
Surgicenters / Rehabilitation																					
Surgery Centers⁽²⁾:																					
Surgery Partners, Inc.	\$39.47	52.9%	140.4%	\$42.87	\$4.00	\$2,302	\$3,258	\$318	\$6,585	\$1,860	\$386	\$200	Dec-20	Dec-20	\$2,085	\$308	\$266	3.5x	17.1x	3.2x	21.4x
Number of Companies	1	Median:	52.9%	140.4%	Total	\$2,302			\$6,585	\$1,860					\$2,085			3.5x	17.1x	3.2x	21.4x
Market Cap. Weighted Average:			52.9%	140.4%														3.5x	17.1x	3.2x	21.4x
Rehabilitation:																					
Encompass Health Corporation	\$80.44	(1.7%)	7.5%	\$88.42	\$48.01	\$7,985	\$3,543	\$224	\$11,737	\$4,644	\$972	\$651	Dec-20	Dec-20	\$5,064	\$946	\$705	2.5x	12.1x	2.3x	12.4x
Select Medical Holdings Corporation	31.65	28.4%	32.2%	32.50	10.00	4,268	4,501	577	8,782	5,532	1,039	507	Dec-20	Dec-20	5,777	803	565	1.6x	8.5x	1.5x	10.9x
U.S. Physical Therapy, Inc.	117.24	9.2%	12.5%	143.67	45.13	1,507	125	33	1,719	418	105	56	Dec-20	Dec-20	472	64	NA	4.1x	16.4x	3.6x	26.9x
Number of Companies	3	Median:	9.2%	12.5%	Total	\$13,759			\$22,237	\$10,594					\$11,312			2.5x	12.1x	2.3x	12.4x
Market Cap. Weighted Average:			8.8%	15.7%														2.4x	11.4x	2.2x	13.5x

Our Firm

Harris Williams has a broad range of industry expertise, which creates powerful opportunities. Our clients benefit from our deep-sector experience, integrated industry intelligence and collaboration across the firm, and our commitment to learning what makes them unique. For more information, visit our website at www.harriswilliams.com/industries.


> Aerospace, Defense & Government Services



> Building Products & Materials



> Business Services



> Consumer



> Energy, Power & Infrastructure



> Healthcare & Life Sciences



> Industrials



> Specialty Distribution



> Technology



> Transportation & Logistics



HARRIS WILLIAMS OFFICE LOCATIONS

UNITED STATES

BOSTON
One International Place
Suite 2620
Boston, Massachusetts 02110
Phone: +1 (617) 482-7501

CLEVELAND
1900 East 9th Street
20th Floor
Cleveland, Ohio 44114
Phone: +1 (216) 689-2400

MINNEAPOLIS
222 South 9th Street
Suite 3350
Minneapolis, Minnesota 55402
Phone: +1 (612) 359-2700

**RICHMOND
(HEADQUARTERS)**
1001 Haxall Point
9th Floor
Richmond, Virginia 23219
Phone: +1 (804) 648-0072

SAN FRANCISCO
One Market Plaza
11th Floor
San Francisco, CA 94105

**WASHINGTON,
D.C.**
800 17th St. NW
2nd Floor
Washington, D.C. 20006
Phone: +1 202-207-2300

UNITED STATES

FRANKFURT
Bockenheimer Landstrasse 33-35
60325 Frankfurt
Germany
Phone: +49 069 3650638 00

LONDON
25 Savile Row
4th Floor
London W1S 2ER, England
Phone: +44 (0) 20 7518 8900

Harris Williams

SOURCES

1. FactSet.
2. S&P.
3. PNC Debt Capital Markets.
4. Company Filings.

DISCLOSURES AND DISCLAIMERS

Investment banking services are provided by Harris Williams LLC (“Harris Williams”). Harris Williams is a registered broker-dealer and member of FINRA and SIPC. Harris Williams & Co. Ltd is a private limited company incorporated under English law with its registered office at 8th Floor, 20 Farringdon Street, London EC4A 4AB, UK, registered with the Registrar of Companies for England and Wales, registration number 07078852. Harris Williams & Co. Ltd is authorized and regulated by the Financial Conduct Authority. Harris Williams & Co. Corporate Finance Advisors GmbH is registered in the commercial register of the local court of Frankfurt am Main, Germany, under HRB 107540. The registered address is Bockenheimer Landstrasse 33-35, 60325 Frankfurt am Main, Germany (email address: hwgermany@harriswilliams.com). Geschäftsführers/Directors: Jeffery H. Perkins, Paul Poggi, VAT No. DE321666994. Harris Williams is a trade name under which Harris Williams LLC, Harris Williams & Co. Ltd and Harris Williams & Co. Corporate Finance Advisors GmbH conduct business.

The information and views contained in this content have been prepared in part by Harris Williams. This content does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate any investment or potential transaction. This content is not a research report, as such term is defined by applicable law and regulations, and is provided for informational purposes only. Any and all information, including estimates, projections and other forward-looking statements, presented in this document may involve various assumptions and significant elements of subjective judgment and analysis that may or may not be correct. Harris Williams has not independently verified, and neither Harris Williams nor any other person will independently verify, any of the information, estimates, projections or forward-looking statements contained herein or the assumptions on which they are based. The information contained in this document is made as of the date hereof unless stated otherwise. Harris Williams does not expect to update or otherwise revise this document nor provide any additional information, nor correct any inaccuracies herein which may become apparent.

This content is intended for institutional use only and should not be relied upon by retail investors or members of the general public. The information contained herein is believed by Harris Williams to be reliable but Harris Williams makes no representation or warranty as to the accuracy or completeness of such information, and information contained herein that is based on material prepared by others may involve significant elements of subjective judgment and analysis which may or may not be correct. Opinions, estimates and projections contained herein constitute Harris Williams’ judgment and are subject to change without notice.

This content is not to be construed as investment advice an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular transaction, nor shall this content form the basis of any contract. It does not constitute and should not be construed as an endorsement or recommendation of any entities’ products or services.

No part of this material may be copied or duplicated in any form or by any means, or redistributed, without Harris Williams’ prior written consent.